Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1) (ARTISTRY-1)

4 ноября 2026 г. обновлено: Gilead Sciences

Рандомизированное, открытое, многоцентровое, активно-контролируемое исследование фазы 2/3 без операционного вмешательства для оценки безопасности и эффективности биктегравира/ленакапавира по сравнению со стабильной базовой схемой у людей с вирусологически подавленным ВИЧ-1, получающих стабильные комплексные схемы лечения

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus current therapy (Phase 2) and BIC/LEN fixed-dose combination (FDC) versus current therapy (Phase 3) in people living with HIV (PWH).

Обзор исследования

Статус

Активный, не рекрутирующий

Условия

Тип исследования

Интервенционный

Регистрация (Действительный)

689

Фаза

  • Фаза 2
  • Фаза 3

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

    • New South Wales
      • Darlinghurst, New South Wales, Австралия, 2010
        • St.Vincent's Hospital Sydney
      • Darlinghurst, New South Wales, Австралия, 2011
        • Taylor Square Private Clinic
      • Sydney, New South Wales, Австралия, 2010
        • Holdsworth House Medical Practice
    • Victoria
      • Melbourne, Victoria, Австралия, 3004
        • Alfred Health
      • Buenos Aires, Аргентина, 1202
        • Fundación Huésped
      • Buenos Aires, Аргентина, 1072
        • Hospital General de Agudos J.M Ramon Mejia
      • Buenos Aires, Аргентина, 1425
        • Helios Salud
      • Berlin, Германия, 10439
        • zibp Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH
      • Bonn, Германия, 53127
        • Universitatsklinikum Bonn
      • Frankfurt, Германия, 60596
        • Infektio Research GmbH & Co.KG
      • Hamburg, Германия, 20146
        • ICH Study Center GmbH & Co. KG
      • München, Германия
        • MVZ München am Goetheplatz
      • Santo Domingo, Доминиканская Респблика
        • Instituto Dominicano de Estudio Virologicos - IDEV
      • Barcelona, Испания, 08036
        • Hospital Clinic Provincial de Barcelona
      • Madrid, Испания, 28040
        • Hospital Clinico San Carlos
      • Madrid, Испания, 28046
        • Hospital Universitario La Paz
      • Madrid, Испания, 28034
        • Hospital Ramon y Cajal, Madrid
      • Seville, Испания, 4103
        • Hospital Universitario Virgen del Rocio
      • Milan, Италия, 20157
        • ASST Fatebenefratelli Sacco
      • Milan, Италия, 20127
        • IRCCS Ospedale San Raffaele
      • Modena, Италия, 40124
        • Azienda Ospedaliero-Universitaria di Modena
      • Roma, Италия, 00149
        • Istituto Nazionale Malattie Infettive "Lazzaro Spallanzani" IRCCS
      • Torino, Италия, 10149
        • ASL Città di Torino
      • Decarie Montreal, Канада, H4A 3J1
        • Chronic Viral Illness Service / McGill University Health Centre (MUHC)
      • Montreal, Канада, H2L 0B1
        • Clinique Medicale du Quartier Latin
      • Ottawa, Канада, K1H 8L6
        • The Ottawa Hospital - General Campus
      • Regina, Канада, S4P 0W5
        • ID Clinic
      • Toronto, Канада, M5G 1K2
        • Maple Leaf Research
      • Vancouver, Канада, V6Z 2T1
        • Spectrum Health
    • PR
      • San Juan, PR, Пуэрто-Рико, 00909
        • Hope Clinical Research
      • San Juan, PR, Пуэрто-Рико, 00935
        • Proyecto ACTU
      • Birmingham, Соединенное Королевство, B9 5SS
        • Department of HIV & Sexual Medicine
      • Brighton, Соединенное Королевство, BN2 3EW
        • Brighton and Sussex University Hospitals NHS Trust
      • London, Соединенное Королевство, E1 1BB.
        • Barts Health NHS Trust
      • London, Соединенное Королевство, SE5 9RS
        • HIV medicine and infectious diseases
      • London, Соединенное Королевство, SW109NH
        • St.Stephen's AIDS Trust, Clinical Trials Unit, 1st Floor, St.Stephen's Centre
    • California
      • Berkeley, California, Соединенные Штаты, 48072
        • Be Well Medical Center
      • Beverly Hills, California, Соединенные Штаты, 90211
        • Pacific Oaks Medical Group
      • Los Angeles, California, Соединенные Штаты, 90036
        • Ruane Clinical Research Group, Inc
      • Oakland, California, Соединенные Штаты, 94609
        • Alta Bates Summit Medical Center, Summit Campus, East Bay Advanced Care
      • Palm Springs, California, Соединенные Штаты, 92262
        • Bios Clinical Research
      • San Diego, California, Соединенные Штаты, 92103
        • University of California San Diego (UCSD)
      • Torrance, California, Соединенные Штаты, 90502
        • Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center
      • West Hollywood, California, Соединенные Штаты, 90046
        • The Men's Health Foundation
    • Colorado
      • Denver, Colorado, Соединенные Штаты, 80204
        • Denver Health Medical Center
    • Connecticut
      • New Haven, Connecticut, Соединенные Штаты, 06510
        • Yale University; School of Medicine; AIDS Program
    • Florida
      • DeLand, Florida, Соединенные Штаты, 32720
        • Midland Florida Clinical Research Center, LLC
      • Fort Lauderdale, Florida, Соединенные Штаты, 33316
        • Gary Richmond, MD, PA, Inc.
      • Fort Lauderdale, Florida, Соединенные Штаты, 33308
        • Therafirst Medical Centers
      • Ft. Pierce, Florida, Соединенные Штаты, 34982
        • Midway Immunology & Research Center, LLC
      • Miami, Florida, Соединенные Штаты, 33136
        • Schiff Center for liver Diseases/University of Miami
      • Miami Lakes, Florida, Соединенные Штаты, 33016
        • Floridian Clinical Research
      • Orlando, Florida, Соединенные Штаты, 32803
        • Orlando Immunology Center
      • Orlando, Florida, Соединенные Штаты, 32803
        • Therapeutic Concepts, PA
      • West Palm Beach, Florida, Соединенные Штаты, 33407
        • Triple O Research Institute PA
    • Georgia
      • Atlanta, Georgia, Соединенные Штаты, 30309
        • Atlanta ID Group
      • Macon, Georgia, Соединенные Штаты, 31201
        • Mercer University School of Medicine
    • Illinois
      • Chicago, Illinois, Соединенные Штаты, 60613
        • Howard Brown Health Center
    • Missouri
      • Kansas City, Missouri, Соединенные Штаты, 64111
        • Kansas City Care Clinic
      • St Louis, Missouri, Соединенные Штаты, 63139
        • Southampton Healthcare, Inc.
    • New Jersey
      • Newark, New Jersey, Соединенные Штаты, 07102
        • Saint Michael's Medical Center
    • New Mexico
      • Santa Fe, New Mexico, Соединенные Штаты, 87505
        • AXCES Research Group
    • New York
      • Flushing, New York, Соединенные Штаты, 11355
        • New York Presbyterian Hospital
      • New York, New York, Соединенные Штаты, 10001
        • Ricky K. Hsu, MD, PC
    • North Carolina
      • Chapel Hill, North Carolina, Соединенные Штаты, 27514
        • University of North Carolina - Chapel Hill
      • Greenville, North Carolina, Соединенные Штаты, 27858
        • East Carolina University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Соединенные Штаты, 19107
        • Philadelphia FIGHT
    • South Carolina
      • Charleston, South Carolina, Соединенные Штаты, 29425
        • Medical University of South Carolina (MUSC) Research NEXUS
    • Texas
      • Austin, Texas, Соединенные Штаты, 78705
        • Central Texas Clinical Research
      • Bellaire, Texas, Соединенные Штаты, 77401
        • St. Hope Foundation
      • Dallas, Texas, Соединенные Штаты, 75246
        • North Texas Infectious Diseases Consultants
      • Dallas, Texas, Соединенные Штаты, 75208
        • AIDS Arms, Inc., DBA Prism Health North Texas
      • Fort Worth, Texas, Соединенные Штаты, 76104
        • Texas Centers for Infectious Disease Associates
      • Houston, Texas, Соединенные Штаты, 77098
        • Gordon E. Crofoot MD PA
      • Longview, Texas, Соединенные Штаты, 75605
        • Diagnostic Clinic of Longview - Center for Clinical Research
    • Washington
      • Seattle, Washington, Соединенные Штаты, 98104
        • Peter Shalit, MD
      • Kaohsiung City, Тайвань, 80756
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Kaohsiung City, Тайвань, 81362
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • New Taipei City, Тайвань, 22060
        • Far Eastern Memorial Hospital
      • Taoyuan City, Тайвань, 33004
        • Taoyuan General Hospital
      • Nice, Франция, 6202
        • CHU Nice-Hôpital l'Archet
      • Paris, Франция, 75010
        • Hospital Saint Louis
      • Paris, Франция, 75018
        • Groupe Hospitalier Bichat Claude Bernard
      • Paris, Франция, 75651
        • Höpital de la Pitié Salpêtrière
      • Cape Town, Южная Африка, 7925
        • Desmond Tutu Health Foundation Clinical Trials Unit
      • Ga-Rankuwa, Южная Африка, 208
        • Sefako Makgatho Health Sciences University
      • Johannesburg, Южная Африка, 2193
        • Ezintsha
      • Daegu, Южная Корея, 41944
        • Kyungpook National University Hospital
      • Daejeon, Южная Корея, 35015
        • Chungnam National University Hospital
      • Seoul, Южная Корея, 06591
        • The Catholic University of Korea Seoul St. Mary's Hospital
      • Seoul, Южная Корея, 03722
        • Yonsei University Severance Hospital
      • Nagoya, Япония
        • National Hospital Organization Nagoya Medical Center
      • Osaka, Япония, 540-0006
        • National Hospital Organization Osaka National Hospital
      • Tokyo, Япония, 162-0052
        • Center Hospital of the National Center for Global Health and Medicine

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Key Inclusion Criteria:

  • If plasma HIV-1 RNA measurements in the 6 months prior to screening are available, all levels must be < 50 copies/mL.

  • At least one documented plasma HIV-1 RNA level measured between 6 and 12 months (± 2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be < 50 copies/mL

  • Plasma HIV-1 RNA levels < 50 copies/mL at screening.

  • Currently receiving a complex antiretroviral (ARV) regimen due to previous viral resistance, or intolerance, or contraindication to existing single-tablet regimens (STR), and on this regimen for at least 6 months prior to the screening visit. The criteria to define a complex regimen in this study are as follows:

    • A regimen containing a boosted protease inhibitor or a nonnucleos(t)ide reverse transcriptase inhibitor (NRTI) plus at least 1 other third agent (ie, an agent from a class other than NRTIs) (eg, bictegravir/emtricitabine/tenofovir alafenamide (coformulated; Biktarvy®)(BVY) + darunavir/cobicistat, BVY + etravirine), or
    • A regimen of ≥ 2 pills/day, or a regimen requiring dosing more than once daily, or
    • A regimen containing parenteral agent(s) (excluding a complete long-acting injectable regimen, such as intramuscular cabotegravir plus rilpivirine) as well as oral agents.
  • No documented or suspected resistance to bictegravir (BIC).

  • Estimated glomerular filtration rate ≥ 15 mL/min according to the Cockcroft-Gault formula for creatinine clearance (CLcr) who are not on renal replacement therapy.

Key Exclusion Criteria:

  • Prior use of, or exposure to, lenacapavir (LEN)
  • Active tuberculosis infection
  • Chronic hepatitis B virus (HBV) infection

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Нет (открытая этикетка)

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg

Participants will switch from their Stable Baseline Regimen (SBR) to a regimen of BIC 75 mg + LEN 25 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day pharmacokinetic (PK) oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 25 mg starting on Day 1.

Participants who discontinue early or complete the Randomized Phase (RP) will have an option to continue in Extension Period (EP)

Tablets administered orally without regard to food

Другие имена:
  • ГС-6207

Tablets administered orally without regard to food

Другие имена:
  • GS-9883
Экспериментальный: Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg

Participants will switch from their SBR to a regimen of BIC 75 mg + LEN 50 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 50 mg starting on Day 1.

Participants who discontinue early or complete the RP will have an option to continue in EP.

Tablets administered orally without regard to food

Другие имена:
  • ГС-6207

Tablets administered orally without regard to food

Другие имена:
  • GS-9883
Активный компаратор: Phase 2: Treatment Group 3: SBR

Participants will continue with their SBR for up to 24 weeks.

Participants who discontinue early or complete the RP will have an option to continue in EP.

SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).

  • Nucleos(t)ide Reverse Transcriptase Inhibitors:

    • Abacavir
    • Emtricitabine
    • Lamivudine
    • Tenofovir alafenamide
    • Tenofovir disoproxil fumarate
    • Zidovudine
  • Non-Nucleosite Reverse Transcriptase Inhibitors:

    • Delavirdine
    • Efavirenz
    • Nevirapine
    • Rilpivirine
    • Doravirine
  • Integrase Inhibitors:

    • Bictegravir
    • Cabotegravir
    • Dolutegravir
    • Elvitegravir
    • Raltegravir
  • Protease Inhibitors:

    • Atazanavir
    • Darunavir
    • Fosamprenavir
    • Indinavir
    • Lopinavir
    • Nelfinavir
    • Saquinavir
    • Tipranavir
  • Chemokine Co-receptor 5 (CCR5) Antagonist:

    • Maraviroc
  • Fusion Inhibitors:

    • Enfuvirtide
  • gp120 Attachment Inhibitor:

    • Fostemsavir
  • Anti-CD4 Monoclonal Antibodies:

    • Ibalizumab-uiyk
Экспериментальный: Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC

Participants will switch from their SBR to a regimen of BIC/LEN 75mg/50mg FDC, administered orally once daily for up to 48 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC/LEN 75 mg/50 mg FDC starting on Day 1.

Participants who discontinue early or complete the RP will have an option to continue in EP.

Tablets administered orally without regard to food

Другие имена:
  • Bixlenvo™
Активный компаратор: Phase 3: Treatment Group 2: SBR

Participants will continue with their SBR for up to 48 weeks.

Participants who will discontinue early or complete the RP had an option to continue in EP.

SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).

  • Nucleos(t)ide Reverse Transcriptase Inhibitors:

    • Abacavir
    • Emtricitabine
    • Lamivudine
    • Tenofovir alafenamide
    • Tenofovir disoproxil fumarate
    • Zidovudine
  • Non-Nucleosite Reverse Transcriptase Inhibitors:

    • Delavirdine
    • Efavirenz
    • Nevirapine
    • Rilpivirine
    • Doravirine
  • Integrase Inhibitors:

    • Bictegravir
    • Cabotegravir
    • Dolutegravir
    • Elvitegravir
    • Raltegravir
  • Protease Inhibitors:

    • Atazanavir
    • Darunavir
    • Fosamprenavir
    • Indinavir
    • Lopinavir
    • Nelfinavir
    • Saquinavir
    • Tipranavir
  • Chemokine Co-receptor 5 (CCR5) Antagonist:

    • Maraviroc
  • Fusion Inhibitors:

    • Enfuvirtide
  • gp120 Attachment Inhibitor:

    • Fostemsavir
  • Anti-CD4 Monoclonal Antibodies:

    • Ibalizumab-uiyk
Экспериментальный: Phase 2/Phase 3:BIC/LEN 75/50 mg FDC

At the end of randomized treatment, participants in Phase 2 and Phase 3 treatment groups who discontinue early or complete the RP will be given an option to enter in EP and will receive BIC/LEN 75/50 mg FDC until the drug is available in market or Gilead elects to withdraw the study. Participants in the SBR groups (Phase 2 Treatment Group 3 and Phase 3 Treatment Group 2 will also receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2 of EP).

Tablets administered orally without regard to food

Другие имена:
  • ГС-6207

Tablets administered orally without regard to food

Другие имена:
  • Bixlenvo™

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm
Временное ограничение: Week 24

Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the week 24 analysis window, or who did not have on-treatment HIV-1 RNA data in the week 24 analysis window and participants who discontinued study drug prior to or in the week 24 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the week 24 analysis window due to adverse event (AE) or death and have the last available on-treatment HIV-1 RNA≥ 50 copies/mL, or who discontinued study drug prior to or in the week 24 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.

Week 24
Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
Временное ограничение: Week 48

Participants who had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to AE or death and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off.

Week 48

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Phase 2: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm
Временное ограничение: Week 24

Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 24 analysis window were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.

Week 24
Phase 2: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 24
Временное ограничение: Baseline, Week 24
Baseline, Week 24
Phase 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 24
Временное ограничение: First dose date up to Week 24

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.

First dose date up to Week 24
Phase 2: PK Parameter: Cmax for Bictegravir (BIC) at Steady State
Временное ограничение: At Week 16 or 24

Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or 24
Phase 2: PK Parameter: Cmax for Lenacapavir (LEN) at Steady State
Временное ограничение: At Week 16 or Week 24

Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 2: PK Parameter: AUCtau of BIC at Steady State
Временное ограничение: At Week 16 or 24

AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or 24
Phase 2: PK Parameter: AUCtau for LEN at Steady State
Временное ограничение: At Week 16 or Week 24

AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 2: PK Parameter: Ctrough of BIC at Steady State
Временное ограничение: At Week 16 or Week 24

Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 2: PK Parameter: Ctrough of LEN at Steady State
Временное ограничение: At Week 16 or Week 24

Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 3: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
Временное ограничение: Week 48

Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively).

Week 48
Phase 3: Change From Baseline in CD4 Cell Count at Week 48
Временное ограничение: Baseline, Week 48

An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.

Baseline, Week 48
Phase 3: Percentage of Participants Experiencing TEAEs Through Week 48
Временное ограничение: First dose date up to Week 48

An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off.

First dose date up to Week 48
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Временное ограничение: Week 96
Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Временное ограничение: Week 144
Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Временное ограничение: Week 96
Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Временное ограничение: Week 144
Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 96
Временное ограничение: Baseline, Week 96
Baseline, Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 144
Временное ограничение: Baseline, Week 144
Baseline, Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 96
Временное ограничение: Week 96
Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 144
Временное ограничение: Week 144
Week 144

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Полезные ссылки

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

16 августа 2022 г.

Первичное завершение (Действительный)

29 сентября 2025 г.

Завершение исследования (Оцененный)

1 декабря 2029 г.

Даты регистрации исследования

Первый отправленный

5 августа 2022 г.

Впервые представлено, что соответствует критериям контроля качества

12 августа 2022 г.

Первый опубликованный (Действительный)

16 августа 2022 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

5 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

4 ноября 2026 г.

Последняя проверка

1 ноября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Дополнительные соответствующие термины MeSH

Другие идентификационные номера исследования

  • GS-US-621-6289
  • 2022-500929-33 (Другой идентификатор: European Medicines Agency)
  • DOH-27-052023-8574 (Другой идентификатор: South African Clinical Trial Registry)
  • jRCT2051230168 (Другой идентификатор: Japan registry)

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

НЕТ

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться